Comparative Safety Analysis of Avastin and Bevacizumab Biosimilars Based on Food and Drug Administration Adverse Event Reporting System
Hypertension, proteinuria, thrombocytopenia, gastrointestinal perforation and thromboembolism remain key concerns. Clinicians should monitor renal and urinary function when administering Avastin. Immune-induced renal disorders associated with biosimilars highlight the importance of assessing the treatment rationale in patients with chronic kidney disease, autoimmune disorders or other comorbid conditions.
Authors
- Yupeng Zhang (ORCID: https://orcid.org/0000-0002-7116-2192)
- Xiaojun Tang (ORCID: https://orcid.org/0000-0003-3486-1020)
- Li Chen (ORCID: https://orcid.org/0000-0002-5771-9740)
- Xiaoyu Zhang (ORCID: https://orcid.org/0000-0001-7528-4405)
Institutions
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Basic & Clinical Pharmacology & Toxicology
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1111/bcpt.70099
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.80